MX2010003013A - Inhibicion de angiogenesis. - Google Patents
Inhibicion de angiogenesis.Info
- Publication number
- MX2010003013A MX2010003013A MX2010003013A MX2010003013A MX2010003013A MX 2010003013 A MX2010003013 A MX 2010003013A MX 2010003013 A MX2010003013 A MX 2010003013A MX 2010003013 A MX2010003013 A MX 2010003013A MX 2010003013 A MX2010003013 A MX 2010003013A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibition
- angiogenesis
- tumor
- antagonists
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
La presente invención es concerniente en general con la inhibición de angiogénesis moderada por células inflamatoria. En particular, la invención es concerniente con la prevención o tratamiento de angiogénesis de tumor y la inhibición de desarrollo del tumor mediante el uso de antagonistas de Bv8, tales como anticuerpos anti-Bv8.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97438207P | 2007-09-21 | 2007-09-21 | |
US8307108P | 2008-07-23 | 2008-07-23 | |
PCT/US2008/076954 WO2009039337A2 (en) | 2007-09-21 | 2008-09-19 | Inhibition of angiogenesis |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2010003013A true MX2010003013A (es) | 2010-08-02 |
Family
ID=40030248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010003013A MX2010003013A (es) | 2007-09-21 | 2008-09-19 | Inhibicion de angiogenesis. |
Country Status (20)
Country | Link |
---|---|
US (1) | US9284369B2 (es) |
EP (1) | EP2203479B1 (es) |
JP (1) | JP5615709B2 (es) |
KR (1) | KR101578945B1 (es) |
CN (1) | CN102037015B (es) |
AR (1) | AR068532A1 (es) |
AU (1) | AU2008302214B2 (es) |
CA (1) | CA2700276A1 (es) |
CL (1) | CL2008002782A1 (es) |
CO (1) | CO6270370A2 (es) |
ES (1) | ES2568881T3 (es) |
HK (1) | HK1141538A1 (es) |
IL (1) | IL204502A (es) |
MX (1) | MX2010003013A (es) |
NZ (1) | NZ584787A (es) |
PE (1) | PE20091197A1 (es) |
RU (2) | RU2471498C2 (es) |
TW (1) | TWI457349B (es) |
WO (1) | WO2009039337A2 (es) |
ZA (1) | ZA201001868B (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101008734B1 (ko) * | 2001-08-29 | 2011-01-14 | 제넨테크, 인크. | 유사분열촉진 활성을 가진 Bv8 핵산 및 폴리펩티드 |
EP2526960A1 (en) | 2003-03-12 | 2012-11-28 | Genentech, Inc. | Use of BV8 and/or EG-VEGF to promote hematopoiesis |
WO2008109377A1 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting vegf family gene expression and uses thereof |
US20110027275A1 (en) | 2009-07-31 | 2011-02-03 | Napoleone Ferrara | Inhibition of tumor metastasis |
ES2743558T3 (es) | 2009-10-14 | 2020-02-19 | Humanigen Inc | Anticuerpos de-EphA3 |
CA2784385A1 (en) * | 2009-12-23 | 2011-06-30 | Genentech, Inc. | Anti-bv8 antibodies and uses thereof |
US9375473B2 (en) | 2010-02-19 | 2016-06-28 | Cornell Research Foundation, Inc. | Method to treat autoimmune demyelinating diseases and other autoimmune or inflammatory diseases |
KR20140068877A (ko) * | 2011-08-17 | 2014-06-09 | 제넨테크, 인크. | 불응성 종양에서의 혈관신생의 억제 |
WO2013082511A1 (en) | 2011-12-02 | 2013-06-06 | Genentech, Inc. | Methods for overcoming tumor resistance to vegf antagonists |
US20150118215A1 (en) * | 2012-03-30 | 2015-04-30 | The General Hospital Corporation | Methods of Inhibiting Cell Proliferation |
TWI498425B (zh) * | 2013-01-08 | 2015-09-01 | Nat Univ Tsing Hua | 層析濾紙型酵素連結免疫吸附分析法 |
WO2014159923A1 (en) * | 2013-03-13 | 2014-10-02 | Health Research, Inc. | Enhancement of vaccines |
CN105848667B (zh) * | 2013-11-22 | 2020-05-19 | 珍白斯凯尔有限公司 | 具有血管生成抑制活性的肽和包含所述肽的组合物 |
CN104237223B (zh) * | 2014-10-08 | 2017-04-12 | 江苏奥赛康药业股份有限公司 | 测定铁‑碳水化合物络合物中不稳定铁含量的方法 |
CN104587469A (zh) * | 2015-01-19 | 2015-05-06 | 马洁 | G-csf拮抗剂在治疗慢性炎症、预防炎症相关肿瘤中的应用 |
CN108699562B (zh) * | 2015-12-03 | 2022-04-22 | 财团法人卫生研究院 | 异质双聚体型血管内皮生长因子及其应用 |
WO2018108862A1 (en) * | 2016-12-12 | 2018-06-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antagonist of prokineticin receptor 2 for use as a medicament for treating an eg-vegf-related cancer |
PL3717011T3 (pl) * | 2017-11-29 | 2023-03-27 | Csl Limited | Sposób leczenia lub zapobiegania uszkodzeniu niedokrwienno- reperfuzyjnemu |
CN116059318A (zh) | 2018-01-26 | 2023-05-05 | 加利福尼亚大学董事会 | 用于使用抗vegf剂治疗血管生成病症的方法和组合物 |
WO2021108255A1 (en) | 2019-11-25 | 2021-06-03 | The Regents Of The University Of California | Long-acting vegf inhibitors for intraocular neovascularization |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9704545D0 (sv) * | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
KR101008734B1 (ko) * | 2001-08-29 | 2011-01-14 | 제넨테크, 인크. | 유사분열촉진 활성을 가진 Bv8 핵산 및 폴리펩티드 |
US7323479B2 (en) * | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
CN1802169A (zh) * | 2003-03-12 | 2006-07-12 | 健泰科生物技术公司 | Bv8和/或EG-VEGF促进造血的用途 |
EP2526960A1 (en) * | 2003-03-12 | 2012-11-28 | Genentech, Inc. | Use of BV8 and/or EG-VEGF to promote hematopoiesis |
CN1829741A (zh) * | 2003-05-30 | 2006-09-06 | 健泰科生物技术公司 | 利用抗-vegf抗体的治疗 |
EP1924603A2 (en) * | 2005-09-13 | 2008-05-28 | Zymogenetics, Inc. | Prok2 antagonists and methods of use |
ITRM20070182A1 (it) * | 2007-04-03 | 2008-10-04 | Univ Roma | Antagonisti dei recettori delle prochineticine derivati di essi e loro uso |
-
2008
- 2008-09-17 CL CL2008002782A patent/CL2008002782A1/es unknown
- 2008-09-19 WO PCT/US2008/076954 patent/WO2009039337A2/en active Application Filing
- 2008-09-19 ES ES08832515.4T patent/ES2568881T3/es active Active
- 2008-09-19 CN CN200880117292.XA patent/CN102037015B/zh not_active Expired - Fee Related
- 2008-09-19 US US12/679,257 patent/US9284369B2/en not_active Expired - Fee Related
- 2008-09-19 NZ NZ584787A patent/NZ584787A/xx not_active IP Right Cessation
- 2008-09-19 TW TW097136179A patent/TWI457349B/zh not_active IP Right Cessation
- 2008-09-19 CA CA2700276A patent/CA2700276A1/en not_active Abandoned
- 2008-09-19 JP JP2010525989A patent/JP5615709B2/ja not_active Expired - Fee Related
- 2008-09-19 KR KR1020107008635A patent/KR101578945B1/ko not_active IP Right Cessation
- 2008-09-19 AU AU2008302214A patent/AU2008302214B2/en not_active Ceased
- 2008-09-19 RU RU2010115755/15A patent/RU2471498C2/ru not_active IP Right Cessation
- 2008-09-19 EP EP08832515.4A patent/EP2203479B1/en active Active
- 2008-09-19 PE PE2008001642A patent/PE20091197A1/es not_active Application Discontinuation
- 2008-09-19 MX MX2010003013A patent/MX2010003013A/es active IP Right Grant
- 2008-09-22 AR ARP080104117A patent/AR068532A1/es unknown
-
2010
- 2010-03-15 IL IL204502A patent/IL204502A/en not_active IP Right Cessation
- 2010-03-16 ZA ZA2010/01868A patent/ZA201001868B/en unknown
- 2010-04-14 CO CO10043417A patent/CO6270370A2/es not_active Application Discontinuation
- 2010-08-12 HK HK10107699.7A patent/HK1141538A1/zh not_active IP Right Cessation
-
2012
- 2012-09-19 RU RU2012140185/15A patent/RU2012140185A/ru not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP5615709B2 (ja) | 2014-10-29 |
CN102037015B (zh) | 2016-02-03 |
NZ584787A (en) | 2012-12-21 |
KR101578945B1 (ko) | 2015-12-21 |
ZA201001868B (en) | 2011-06-29 |
CO6270370A2 (es) | 2011-04-20 |
CL2008002782A1 (es) | 2009-07-31 |
US9284369B2 (en) | 2016-03-15 |
CA2700276A1 (en) | 2009-03-26 |
EP2203479B1 (en) | 2016-01-27 |
KR20100075513A (ko) | 2010-07-02 |
WO2009039337A2 (en) | 2009-03-26 |
IL204502A (en) | 2015-05-31 |
RU2010115755A (ru) | 2011-10-27 |
US20100316633A1 (en) | 2010-12-16 |
ES2568881T3 (es) | 2016-05-05 |
EP2203479A2 (en) | 2010-07-07 |
JP2010540449A (ja) | 2010-12-24 |
CN102037015A (zh) | 2011-04-27 |
TW200920750A (en) | 2009-05-16 |
TWI457349B (zh) | 2014-10-21 |
PE20091197A1 (es) | 2009-08-14 |
HK1141538A1 (zh) | 2010-11-12 |
AU2008302214A1 (en) | 2009-03-26 |
WO2009039337A3 (en) | 2009-05-14 |
AU2008302214B2 (en) | 2012-10-25 |
RU2012140185A (ru) | 2014-03-27 |
RU2471498C2 (ru) | 2013-01-10 |
AR068532A1 (es) | 2009-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2010003013A (es) | Inhibicion de angiogenesis. | |
MX2012001306A (es) | Inhibicion de matastasis de tumor. | |
IN2012DN03883A (es) | ||
MX2011009539A (es) | 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso. | |
MX354099B (es) | Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama. | |
MY161495A (en) | Virus like particle compositions and methods of use | |
JO2931B1 (en) | Double-substituted phthalazin compounds as antagonists of the cell-specific factor pathway | |
EA201200473A1 (ru) | Замещенные (гетероарилметил)тиогидантоины | |
MX2010006823A (es) | Metodos para el tratamiento de la gota. | |
MX2019000225A (es) | Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades. | |
WO2012088266A3 (en) | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 | |
IN2012DN02046A (es) | ||
MY172372A (en) | Compositions and methods for lowering triglycerides | |
MY160399A (en) | Compounds, compositions, and methods for preventing metastasis of cancer cells | |
MX345909B (es) | Anticuerpos anti-fgfr3 y métodos que los utilizan. | |
MX2011014019A (es) | Derivados de diazahomoadamantano y sus metodos de uso. | |
WO2012170776A3 (en) | Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy | |
MX2010006933A (es) | Composiciones y metodos para reducir o prevenir la deshidratación de la piel. | |
WO2011130164A3 (en) | Unconjugated anti-tfr antibodies and compositions thereof for the treatment of cancer | |
UA102250C2 (ru) | Двухзамещенные фталазины - антагонисты проводящего пути hedgehog | |
IN2012DN02624A (es) | ||
JO3437B1 (ar) | أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها | |
TN2011000166A1 (en) | Disubstituted phthalazine hedgehog pathway antagonists | |
MX2009012421A (es) | Inhibicion de metastasis de tumor por anticuerpos anti neuropilina 2. | |
PH12013502194A1 (en) | Antibodies to egfl7 and methods for their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |